SEC Form 3 · accession 0001213900-18-001451
Actinium Pharmaceuticals, Inc. · ATNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anil Kapur
Officer — Chief Commercial Officer
Period of report
Feb 6, 2018
Accepted (ET)
Feb 8, 2018 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 40,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $0.64 | holding | — | — | — | Feb 6, 2018 | Feb 6, 2028 | Common Stock | 475,000 | — | D |
Explanation of responses
- F1Options granted on February 6, 2018 to purchase an aggregate of 475,000 shares of common stock. A total of 28% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal increments of 2% per month of the initial option grant over the following three year period.